Zolpidem

Limits on what this shows

• Key negative/null findings: Berson 2001 is itself the key null/negative finding for a mitochondrial-burden claim: the same experimental system that showed clear toxicity for alpidem showed none for zolpidem.
• At-risk subgroups: None established; both studies are preclinical (isolated rat hepatocytes; cell culture) and do not establish a human at-risk population.
• Counter-evidence on record: No study was found showing zolpidem itself impairing mitochondrial membrane potential, electron-transport-chain activity, or biogenesis at therapeutic-relevant concentrations.

Regulatory status

Not addressed in the FDA label.

Population evidence

Berson A, et al., "Toxicity of alpidem, a peripheral benzodiazepine receptor ligand, but not zolpidem, in rat hepatocytes: role of mitochondrial permeability transition and metabolic activation," PMID 11602696 (2001) - zolpidem was tested directly (not merely by class extrapolation) alongside alpidem in rat hepatocytes; alpidem caused mitochondrial permeability transition and hepatocyte toxicity via metabolic (CYP-mediated) activation, while zolpidem specifically did not. Jazvinscak Jembrek M, et al., "Neuroprotective effect of zolpidem against glutamate-induced toxicity is mediated via the PI3K/Akt pathway and inhibited by PK11195," PMID 29859204 (2018) - in cell culture, zolpidem's neuroprotection against glutamate excitotoxicity was blocked by PK11195, a ligand of the mitochondrial translocator protein (TSPO, the outer-mitochondrial-membrane receptor formerly called the peripheral benzodiazepine receptor), implicating a mitochondria-associated receptor in the protective mechanism.

Mechanism

Zolpidem is GABA-A alpha-1-selective at its primary target and, per these two Tier B studies, does not share the CYP-mediated metabolic-activation/mitochondrial-permeability-transition liability of the structurally related, since-withdrawn compound alpidem; its neuroprotective signal in cell culture involves TSPO, a mitochondrial outer-membrane protein, in a protective rather than burdensome direction.

Counter-evidence held on record

This is preclinical, mechanistic evidence pointing away from mitochondrial harm, not toward it - it should not be marketed as a protective health claim ("zolpidem protects your mitochondria") any more than a depletion claim would be justified. Present as reassuring mechanistic context only.

Limits on what this shows

• Key negative/null findings: No study identified found zolpidem to increase oxidative-stress markers (lipid peroxidation, protein carbonylation, reduced glutathione) at therapeutic-relevant exposures; all located studies describe a neutral-to-protective direction.
• At-risk subgroups: None established; all studies are preclinical (in vitro, animal, or computational) and none establishes a human clinical population or dosing implication.
• Counter-evidence on record: None found suggesting a pro-oxidant or depleting effect; the absence of any contrary Tier B finding is itself notable and is why this entry is graded on the protective side rather than left ungraded.

Regulatory status

Not addressed in the FDA label.

Population evidence

Garcia-Santos G, Herrera F, Martin V, et al., "Antioxidant activity and neuroprotective effects of zolpidem and several synthesis intermediates," PMID 15763953 (2004) - measured direct antioxidant activity of zolpidem in vitro. Yousefsani BS, Akbarizadeh N, Pourahmad J, "The antioxidant and neuroprotective effects of Zolpidem on acrylamide-induced neurotoxicity using Wistar rat primary neuronal cortical culture," PMID 32025499 (2020) - zolpidem reduced acrylamide-induced oxidative neurotoxicity in primary rat cortical neurons. Kumar A, Goyal R, "Possible GABAergic modulation in the protective effect of zolpidem in acute hypoxic stress-induced behavior alterations and oxidative damage," PMID 17768679 (2008) - zolpidem reduced hypoxic-stress-induced oxidative damage in an animal model, an effect attributed to GABAergic modulation. Bortoli M, Dalla Tiezza M, Muraro C, et al., "Psychiatric Disorders and Oxidative Injury: Antioxidant Effects of Zolpidem Therapy disclosed In Silico," PMID 30867894 (2019) - computational/in silico modeling of zolpidem's antioxidant chemistry. Kovacic P, Somanathan R, PMID 20046645 (2009) - mechanistic review concluding zolpidem alters synaptic GABA activity "without significant free radical generation," distinguishing it from drug classes that do generate significant radicals.

Mechanism

Multiple independent lines (direct radical-scavenging assay, animal hypoxic-stress model, primary-neuron culture, and computational modeling) converge on zolpidem having intrinsic antioxidant/radical-scavenging chemistry rather than pro-oxidant activity, and on an absence of significant free-radical generation by the drug itself.

Counter-evidence held on record

This is preclinical mechanistic evidence, not a demonstrated clinical antioxidant benefit in humans. It should never be marketed as "zolpidem protects against oxidative stress" as a health claim, and it does not support any antioxidant-supplement recommendation in either direction.

Limits on what this shows

• Why no grade: Both conditions for ungraded are met. A PubMed search for "zolpidem copper" returned five results: two organic-chemistry synthesis papers using copper catalysts to manufacture zolpidem/alpidem (irrelevant to biological copper status), an unrelated traumatic-brain-injury essential-metals review that does not stratify by zolpidem use, and Poujois A, Pernon M, Trocello JM, Woimant F, "Dystonic Dysarthria in Wilson Disease: Efficacy of Zolpidem," PMID 29163329 (2017), a case report using zolpidem as symptomatic therapy for dystonic dysarthria in a patient with Wilson disease (a copper-overload disorder). A follow-up abstract-level pull of this paper (via OpenAlex's per-PMID lookup) confirms it reports only speech and fluency measures, semantic fluency, spontaneous speech rate, and reading rate, all improving after zolpidem, with no measurement of copper, ceruloplasmin, or Wilson-disease activity anywhere in the abstract; it uses zolpidem's known paradoxical-arousal pharmacology to treat a symptom in a patient whose underlying disease happens to be copper-related, which is a coincidental cohort overlap, not a copper-status finding, and is excluded from grading on that basis, now confirmed at full-abstract level rather than title level alone. A broadened class-level PubMed query, "zolpidem OR zaleplon OR eszopiclone OR z-drug" combined with copper, returned the same five zolpidem-era results plus one addition, Suhas KP, Kumawat A, Galla MS, Shankaraiah N, "A rapid regioselective C3-functionalization of 7-phenylpyrazolo[1,5-a]pyrimidines: en route to the synthesis of zaleplon and reversan drugs," PMID 42478948 (2026), itself another copper-catalyzed synthesis method paper, not a biological finding, confirming the gap holds at the Z-drug class level, not only for zolpidem specifically. No claim about zolpidem and copper was encountered in the consumer-facing sources checked (Drugs.com, RxList) or in any circulating depletion narrative tested elsewhere in this dossier.

Tooling disclosure

This category received a dedicated, unshared re-research pass across every channel this protocol requires, run solo with a full tool budget rather than a budget shared across concurrent subagents. PubMed's search-listing page was reachable and returned genuine, on-topic (if irrelevant) results at both the drug-specific and the broadened class level, so this is confirmed as a real literature gap, not a tooling failure. Europe PMC's REST API returned a genuine HTTP 429 on the first retry attempt this pass, and the fetch layer itself then returned an explicit instruction not to retry that endpoint again this session, so no direct Europe PMC confirmation was obtained despite the attempt. The Semantic Scholar Graph API's paper-search endpoint was queried three separate times, spaced roughly one to two minutes apart, and returned a genuine target-side HTTP 429 on every attempt, confirming persistent rate limiting rather than a single transient block. OpenAlex's own search endpoint was queried the same number of times with the same spacing and likewise returned a genuine target-side HTTP 429 every time; its separate per-PMID lookup endpoint, however, was reachable throughout and was used successfully to pull the full abstract for the Wilson-disease case report cited above. This category is now treated as fully re-searched across every channel reachable this pass. Europe PMC, Semantic Scholar's search endpoint, and OpenAlex's search endpoint remain genuinely rate-limited rather than unattempted, and a future revision should retry them only if independent confirmation of this null result is judged worth the wait; no result found so far, at drug or class level, across any channel, points toward a real copper signal.

Limits on what this shows

• Why no grade: Both conditions for ungraded are met. A PubMed search for "zolpidem iron" surfaced Yamagishi Y, Nagasawa S, Iwase H, Ogra Y, "Identification of post-mortem product of zolpidem degradation by hemoglobin via the Fenton reaction," PMID 38825485 (2024), a forensic toxicology/analytical chemistry study describing how zolpidem chemically degrades after death via iron-catalyzed Fenton-reaction chemistry involving hemoglobin's iron. A follow-up abstract-level pull of this paper (via OpenAlex's per-PMID lookup) confirms it is entirely about identifying a postmortem degradation product to explain why blood zolpidem concentrations at autopsy differ from death-time estimates, validated in actual autopsy cases; it contains no measurement of a living patient's iron status, absorption, or metabolism, and is excluded from grading on that basis, now confirmed at full-abstract level rather than title level alone. The remaining results (a restless-legs-syndrome treatment review that discusses iron supplementation and zolpidem as two separate, unrelated interventions in the same review; a veterinary poisoning case-series; a TBI essential-metals review not stratified by zolpidem; a chronic-kidney-disease insomnia-management survey and a plasma solid-phase-extraction method paper) are similarly non-applicable. A broadened class-level PubMed query, "zolpidem OR zaleplon OR eszopiclone OR z-drug" combined with iron, returned the same 12-result set with no additional paper, confirming the gap holds at the Z-drug class level, not only for zolpidem specifically. No claim about zolpidem and iron was encountered in the consumer-facing sources checked.

Tooling disclosure

This category received the same dedicated, unshared re-research pass as Copper, run solo with a full tool budget. PubMed's search-listing page was reachable and returned genuine, on-topic results at both the drug-specific and the broadened class level, confirming a real literature gap rather than a tooling failure. Europe PMC's REST API returned a genuine HTTP 429 on this pass's retry attempt, and the fetch layer itself then returned an explicit instruction not to retry that endpoint again this session, so no direct Europe PMC confirmation was obtained despite the attempt. The Semantic Scholar Graph API's paper-search endpoint was queried three separate times, spaced roughly one to two minutes apart, and returned a genuine target-side HTTP 429 on every attempt, confirming persistent rate limiting rather than a single transient block. OpenAlex's own search endpoint was queried the same number of times with the same spacing and likewise returned a genuine target-side HTTP 429 every time; its separate per-PMID lookup endpoint, however, was reachable throughout and was used successfully to pull the full abstract for the Yamagishi 2024 paper cited above. This category is now treated as fully re-searched across every channel reachable this pass. Europe PMC, Semantic Scholar's search endpoint, and OpenAlex's search endpoint remain genuinely rate-limited rather than unattempted, and a future revision should retry them only if independent confirmation of this null result is judged worth the wait; no result found so far, at drug or class level, across any channel, points toward a real iron signal.

Limits on what this shows

• Key negative/null findings: The pooled/class-level estimate across all six GABA-modulators was null (OR 1.07, ns). This is itself useful counter-evidence: the zolpidem-specific point estimate is higher than the class average, but the confidence interval is wide and crosses the null, so this is a trend requiring a larger, purpose-built study, not an established finding.
• At-risk subgroups: Not separately reported by age, sex, or exposure duration in the data retrieved.
• Counter-evidence on record: This is a single case-control study (292 cases total across all drugs studied, not zolpidem alone) with a non-significant zolpidem-specific estimate; the authors themselves describe it as warranting reassessment in an appropriately powered study, not as a confirmed association.

Regulatory status

Not addressed in the FDA label.

Population evidence

Strom J, Tham J, Mansson F, Ahl J, Savidge TC, Dann SM, Resman F, "The Association between GABA-Modulators and Clostridium difficile Infection - A Matched Retrospective Case-Control Study," PMID 28060888 (2017). Matched retrospective case-control study, Skane county, Sweden, July-December 2013, 292 CDI cases matched with controls; drugs examined were zolpidem, zopiclone, benzodiazepines, gabapentin, pregabalin, and baclofen. Pooled GABA-modulator odds ratio was not significant (OR 1.07, 95% CI 0.69-1.66, p=0.76), but zolpidem specifically showed OR 2.31 (95% CI 0.91-5.86, p=0.078), essentially unchanged after propensity-score adjustment (OR 2.52, 95% CI 0.91-6.97, p=0.075).

Mechanism

Not established. GABAergic modulation of enteric neurons and gut motility/transit time is biologically plausible as a route to altering the luminal environment that shapes microbial competition (mechanism class G, gut transit alteration), but this is the authors' own stated rationale for testing the drug class, not a confirmed mechanism for zolpidem.

Counter-evidence held on record

Do not present this as "zolpidem disrupts your gut microbiome" or "causes C. difficile infection." The confidence interval crosses 1; this is a single underpowered signal that needs replication, not an established drug effect, and no probiotic or supplement recommendation follows from a yellow-tier, non-significant finding.

Limits on what this shows

• Key negative/null findings: A targeted PubMed search for zolpidem combined with hemoglobin, anemia, or oxygen did not surface any controlled study measuring hemoglobin, hematocrit, or erythropoietic parameters in zolpidem-treated patients; the only population-level data found is the label's own rare-frequency listing, with no denominator, dose-response, or exposure-duration data available to characterize it further.
• At-risk subgroups: None specifically identified by the label for this signal. General label-based risk modifiers (women, given slower clearance and higher exposure at a given dose; hepatic impairment, given reduced drug clearance) are plausible exposure modifiers but are not specifically linked to the hematologic terms in the label text.
• Counter-evidence on record: The label explicitly frames its preapproval "Rare" category as drawn from a large multiple-dose trial database without implying causality for any individual term, and the postmarketing-experience subsection (section 6.2, active spontaneous surveillance since approval) does not repeat any of these hematologic terms - if this were a robust, dose-related signal it would be expected to also surface there.

Regulatory status

FDA label, section 6.1 ("Adverse Event Incidence Across the Entire Preapproval Database"), verbatim: "Hematologic and lymphatic system: Rare: anemia, hyperhemoglobinemia, leukopenia, lymphadenopathy, macrocytic anemia, purpura, thrombosis." "Rare" is defined in the same section as an event rate of less than 1 in 1,000 patients. This is from the controlled preapproval trial database, not spontaneous postmarketing reporting; section 6.2 (Postmarketing Experience) lists only hepatobiliary injury and delirium, with no additional hematologic terms.

Population evidence

Confirmed by direct retrieval of the current FDA-approved label text (accessdata.fda.gov, NDA 019908, 2022 labeling); independently corroborated in overlapping form by two consumer drug-information aggregators (Drugs.com and RxList), which list the same or a near-identical set of terms (anemia, hyperhemoglobinemia, leukopenia, lymphadenopathy, macrocytic anemia, purpura, thrombosis, increased ESR) as sourced from professional/label-derived content - cited here only as corroborating secondary aggregation, not as the primary evidentiary basis, per this protocol's Tier D rule.

Mechanism

Not established. No hemolytic, marrow-suppressive, or nutrient-cofactor mechanism is named in the label or in any mechanistic literature found for zolpidem specifically.

Counter-evidence held on record

This is a rare, label-listed signal without an established mechanism or causal confirmation, not a demonstrated or dose-dependent effect. Do not present this as "zolpidem causes anemia." The term "macrocytic anemia" in particular must not be read as evidence of vitamin B12 or folate deficiency - no study identified measured B12, folate, or homocysteine in association with this signal. If unexplained anemia or cytopenia is identified in a patient on zolpidem, standard clinical hematologic workup is appropriate, not empirical supplementation.

Limits on what this shows

• Key negative/null findings: Berson A, De Beco V, Letteron P, Robin MA, Moreau C, El Kahwaji J, Verthier N, Feldmann G, Fromenty B, Pessayre D, "Toxicity of alpidem, a peripheral benzodiazepine receptor ligand, but not zolpidem, in rat hepatocytes: role of mitochondrial permeability transition and metabolic activation," PMID 11602696 (2001) - directly tested zolpidem alongside the structurally related compound alpidem in rat hepatocytes and found zolpidem did not trigger the mitochondrial permeability transition or hepatocyte toxicity that alpidem did, a relevant negative/reassuring finding for cellular energy machinery, cited primarily under Mitochondrial burden below (see Overlap note).
• At-risk subgroups: The Gillin 1996 effect is described as plasma-concentration-dependent, so it would be expected to track with factors that raise exposure at a given dose (e.g., female sex, hepatic impairment, per the PK basis above) - this is a pharmacokinetic exposure point, not an at-risk-for-deficiency population.
• Counter-evidence on record: No study identified measured resting/baseline (non-sedated) cellular ATP production or mitochondrial ATP-synthase activity as reduced by chronic zolpidem exposure in humans; the PET finding is specific to the acute, reversible, sedated state.

Regulatory status

Not addressed in the FDA label.

Population evidence

Gillin JC, Buchsbaum MS, Valladares-Neto DC, Hong CC, Hazlett E, Langer SZ, Wu J, "Effects of zolpidem on local cerebral glucose metabolism during non-REM sleep in normal volunteers: a positron emission tomography study," PMID 8873114 (1996), conducted at UC San Diego. Healthy volunteers received zolpidem and underwent PET imaging of local cerebral glucose metabolism during non-REM sleep; regional (including thalamic) glucose-metabolism changes varied directly with plasma zolpidem concentration. Full quantitative effect sizes were not independently retrievable during this review (see Sources); this is cited at the level of the study's own reported directional finding.

Mechanism

GABA-A alpha-1 receptor potentiation reduces regional neuronal activity as part of the drug's intended sedative-hypnotic action; reduced neuronal firing lowers regional glucose utilization, which PET measures as reduced glucose metabolism. This is the drug's own designed pharmacodynamic effect on brain activity, not a mitochondrial ATP-synthase defect or a nutrient-cofactor-mediated impairment of energy-production capacity (Hard Rule 2: a drug's own intended pharmacologic effect is not a nutrient-deficiency finding).

Counter-evidence held on record

This must not be presented as "zolpidem depletes your cellular energy/ATP." The PET finding reflects transient, reversible, dose-tracking reduction in regional brain activity during sedation - the drug working as intended - not a lasting impairment of mitochondrial ATP-synthesis capacity. No supplement or dosing claim follows from this entry.